| Not Yet Recruiting | A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology NCT07481019 | National University Hospital, Singapore | N/A |
| Not Yet Recruiting | Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Pat NCT07485764 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 |
| Not Yet Recruiting | A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis NCT07489885 | InventisBio Co., Ltd | Phase 2 |
| Not Yet Recruiting | Psoriasis Comorbidities at Hospital Calderón Guardia NCT07448337 | Caja Costarricense de Seguro Social | — |
| Not Yet Recruiting | Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease NCT07448402 | Caja Costarricense de Seguro Social | — |
| Not Yet Recruiting | Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis NCT07366268 | Assiut University | N/A |
| Not Yet Recruiting | An AI-Based Erythema Measurement System for Psoriasis Lesions NCT07494396 | Khon Kaen University | — |
| Not Yet Recruiting | Assessing Psoriasis Treatment Outcomes NCT07391423 | Wake Forest University Health Sciences | N/A |
| Not Yet Recruiting | The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease NCT07487831 | University of California, San Francisco | Phase 4 |
| Not Yet Recruiting | Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in T NCT07434076 | Shanghai Yueyang Integrated Medicine Hospital | — |
| Suspended | Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis NCT06723171 | Io Therapeutics | Phase 2 |
| Recruiting | A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects W NCT07471048 | Sirt3 LLC | N/A |
| Not Yet Recruiting | Methotrexate Versus Apremilast for Pruritus in Psoriasis NCT07432386 | Zarmeen Khawar | Phase 4 |
| Recruiting | A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis NCT07449234 | Janssen-Cilag Ltd. | — |
| Recruiting | Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) NCT07234838 | Jonathan Krygier | — |
| Not Yet Recruiting | A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque NCT07382388 | Peking University Third Hospital | — |
| Enrolling By Invitation | Thera-Clean® Microbubbles System in Patients With Skin Diseases NCT07050810 | Northwestern University | EARLY_Phase 1 |
| Not Yet Recruiting | LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in NCT07336641 | Fondazione ISIDE | — |
| Not Yet Recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis NCT07352566 | University of California, San Francisco | Phase 4 |
| Recruiting | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and NCT07340216 | Arcutis Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Tri NCT07194200 | Shenzhen People's Hospital | Phase 2 |
| Not Yet Recruiting | Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers NCT07254325 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 1 |
| Recruiting | PALLAS Laser for Skin Diseases NCT07250997 | Szeged University | N/A |
| Recruiting | A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Ps NCT07265284 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 3 |
| Recruiting | Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), Wit NCT07258745 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Recruiting | Real-Life Evaluation of Guselkumab Dosing Interval Adjustments NCT07430319 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | SEquential Treatment of PSoriasis With Biologics NCT07187817 | Royal United Hospitals Bath NHS Foundation Trust | — |
| Recruiting | Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS? NCT07289399 | Cairo University | N/A |
| Not Yet Recruiting | A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients with Psoriasis NCT06620692 | Xantho Biotechnology Co., LTD | Phase 2 |
| Not Yet Recruiting | Characterization of the Fungal Immunopeptidome Involved in the Immunopathological Mechanisms of Psoriasis NCT06610942 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Safety and Efficacy of RAP-103 to Improve Severity and Quality of Life on Moderate to Severe Psoriasis in Subj NCT07204639 | Clarent Biopharma, Inc. | Phase 2 |
| Not Yet Recruiting | Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis NCT07190391 | Daewoong Pharmaceutical Co. LTD. | — |
| Not Yet Recruiting | A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis NCT07150988 | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Pathogenesis of Periodontal Disease in Individuals With Psoriasis NCT07158125 | Recep Tayyip Erdogan University Training and Research Hospital | — |
| Withdrawn | Koebner's Phenomenon in Psoriasis and Lichen Planus NCT06021405 | Marie-Charlotte Brüggen | N/A |
| Not Yet Recruiting | Is Monitoring Enhanced Auto-fluorescence Beneficial for the Precise Removal of Tissue From Psoriatic Lesions W NCT07130019 | Nick van der Beek | N/A |
| Active Not Recruiting | Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability NCT07321288 | Chinese PLA General Hospital | — |
| Recruiting | Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction NCT07183423 | Makati Medical Center | N/A |
| Recruiting | Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis NCT07261306 | Lahore General Hospital | EARLY_Phase 1 |
| Active Not Recruiting | A Trial of SHR-1139 in Healthy Volunteers NCT07078695 | Atridia Pty Ltd. | Phase 1 |
| Recruiting | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy NCT07256015 | Bristol-Myers Squibb | — |
| Recruiting | Evaluation of IL 12B Genetic Polymorphism (rs3213094) NCT07128472 | South Valley University | N/A |
| Recruiting | A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic NCT07149792 | Taichung Veterans General Hospital | Phase 4 |
| Recruiting | Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? NCT06742333 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Not Yet Recruiting | Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients NCT06702293 | National University Hospital, Singapore | N/A |
| Withdrawn | Adherence to Otezla NCT05601492 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Recruiting | Genetic Variation in TRAF3IP2 (rs13190932) NCT07086924 | South Valley University | N/A |
| Recruiting | Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118 NCT07033234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 NCT06846710 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Assessment of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psorias NCT06735911 | Thermes de Bareges | N/A |
| Enrolling By Invitation | A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous NCT06999941 | Xi Tan | — |
| Completed | Periodontal Health and Quality of Life in Psoriasis Patients NCT07154420 | Saglik Bilimleri Universitesi | — |
| Not Yet Recruiting | A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis NCT06926582 | Hansoh BioMedical R&D Company | Phase 2 |
| Recruiting | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439 NCT06857942 | Eli Lilly and Company | Phase 4 |
| Not Yet Recruiting | A Basket Trial of Vunakizumab in Inflammatory Skin Diseases NCT06794671 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Effect of Addition of Pyramidal Exercise to Intermittent Fasting on Dryness of Eye in Pre-diabetic Psoriasis P NCT06893913 | Cairo University | N/A |
| Recruiting | Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable M NCT06800755 | Pierre Fabre Dermo Cosmetique | N/A |
| Completed | A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement NCT07066150 | Shanghai Chicmax Cosmetic Co., Ltd. | N/A |
| Completed | Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepre NCT07432815 | Cairo University | Phase 4 |
| Recruiting | A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France NCT06701513 | Bristol-Myers Squibb | — |
| Active Not Recruiting | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanes NCT06952465 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis NCT06846541 | Alumis Inc | Phase 3 |
| Recruiting | Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout NCT05725876 | University Medical Center Groningen | Phase 1 |
| Recruiting | Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After I NCT06574178 | University of California, Davis | N/A |
| Recruiting | Dietary Approach to Mild-to-moderate Psoriasis NCT05644782 | University of Palermo | N/A |
| Completed | Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone NCT07375654 | Cairo University | Phase 1 |
| Completed | Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets NCT06610890 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | Evaluation of Salivary and Serum Levels of TNF-α, IL-17A, and YKL-40 in Individuals With Psoriasis NCT06984237 | Akdeniz University | — |
| Completed | IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients NCT06729463 | South Valley University | N/A |
| Not Yet Recruiting | A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis NCT06672393 | Hansoh BioMedical R&D Company | Phase 3 |
| Completed | Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis NCT06640114 | Efferon JSC | N/A |
| Not Yet Recruiting | Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic NCT06599411 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and NCT06588283 | Eli Lilly and Company | Phase 3 |
| Completed | Bioequivalence Test of Hemay005 Tablets NCT06610903 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) NCT06792487 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | HPP737 Substance Balance Study in Human NCT06584058 | Newsoara Biopharma Co., Ltd. | N/A |
| Active Not Recruiting | Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis NCT06398652 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 3 |
| Active Not Recruiting | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring NCT06710470 | Bristol-Myers Squibb | — |
| Recruiting | A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus St NCT07532486 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Walk and Talk: Connecting People With Psoriasis NCT06726213 | Royal Free Hospital NHS Foundation Trust | N/A |
| Not Yet Recruiting | Cream Containing Sericin and Turmeric in Psoriasis Patients NCT06482398 | Chulalongkorn University | N/A |
| Not Yet Recruiting | Comprehensive Intervention of Diabetes and Psoriasis Comorbidity Prevention and Control NCT06402760 | Shanghai Yueyang Integrated Medicine Hospital | EARLY_Phase 1 |
| Terminated | TYK2 Inhibition in Paradoxical Psoriasis NCT06281106 | Prof Curdin Conrad | Phase 2 / Phase 3 |
| Completed | Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care NCT07428954 | AI Labs Group S.L | — |
| Not Yet Recruiting | Low-Dose Enoxaparin in Psoriasis NCT06416566 | Zagazig University | N/A |
| Completed | To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment NCT06380153 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque NCT06247319 | AbbVie | — |
| Recruiting | To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage NCT06376474 | Ganzhou Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients NCT06357221 | Galderma R&D | Phase 4 |
| Recruiting | Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis NCT06448689 | ActiGraph L.L.C | — |
| Completed | Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients NCT06101706 | Centre Hospitalier Henri Duffaut - Avignon | N/A |
| Completed | Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin NCT06324695 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Unknown | Involvement of Pollutants in Atopic Dermatitis and Psoriasis NCT06213688 | Assistance Publique Hopitaux De Marseille | N/A |
| Recruiting | Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis NCT06477237 | Huabo Biopharm Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of P NCT06055699 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versu NCT06126718 | BioRay Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Impact of the Mediterranean Diet on Patients with Psoriasis NCT06257641 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | N/A |
| Completed | A Clinical Trial of TQH3906 Capsules in Healthy Volunteers NCT06230588 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Role of Insulin Action in Psoriasis Pathogenesis NCT06242847 | Columbia University | — |
| Unknown | Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases NCT06277635 | Phramongkutklao College of Medicine and Hospital | N/A |
| Completed | Smart Phone Delivered Cognitive Behavioral Therapy for Adults With Psoriasis and Co-Morbid Depression Symptoms NCT06216691 | Brigham and Women's Hospital | N/A |
| Completed | The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia. NCT07046039 | King Abdulaziz University | — |
| Completed | Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream NCT06180473 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermat NCT06319781 | Blueskin AS | — |
| Completed | An Exploratory Study to Evaluate a Digital Intervention to Disrupt Scratching in Atopic Dermatitis and Psorias NCT06275659 | Click Therapeutics, Inc. | N/A |
| Completed | Pythagorean Self-Awareness Intervention on Psoriasis Patients. NCT06691763 | National and Kapodistrian University of Athens | N/A |
| Completed | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] NCT05796245 | Pfizer | — |
| Completed | Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis NCT05725057 | Artax Biopharma Inc | Phase 1 / Phase 2 |
| Completed | A Clinical Study of TQH2929 in Healthy Adult Subjects NCT06156280 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adu NCT05959070 | AbbVie | — |
| Completed | A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis NCT06073119 | Sanofi | Phase 2 |
| Completed | Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biologica NCT07498543 | Catholic University of the Sacred Heart | — |
| Completed | IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment NCT06049810 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Completed | CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study NCT06050330 | Sohag University | N/A |
| Unknown | A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis NCT06077331 | Hansoh BioMedical R&D Company | Phase 2 |
| Completed | To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis NCT06061471 | Akeso | Phase 2 |
| Completed | Impact of Clinical and Psychological Factors on Treatment Satisfaction in Psoriatic Patients in Biological The NCT06102356 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Effectiveness of a Digital Health Application for Psoriasis NCT06027034 | Gaia AG | N/A |
| Completed | A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics NCT05970978 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Unknown | A Study to Evaluate the Efficacy and Safety of LZM012 NCT06110676 | Livzon Pharmaceutical Group Inc. | Phase 3 |
| Completed | Efficacy of Pulsed High Intensity Laser Therapy in Psoriatic Hand Arthritis NCT06665282 | Cairo University | N/A |
| Active Not Recruiting | Deucravacitinib Adherence Study NCT05570955 | Wake Forest University Health Sciences | N/A |
| Recruiting | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620 | Brain Inflammation Collaborative | — |
| Recruiting | HIPPOCRATES Prospective Observational Study NCT05858528 | University of Oxford | — |
| Active Not Recruiting | Tilrdakizumab Almirall NCT07244744 | University Hospital Schleswig-Holstein | — |
| Active Not Recruiting | Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis NCT05908240 | University of Pennsylvania | N/A |
| Unknown | A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological NCT05084417 | OM1, Inc. | — |
| Recruiting | IMPACT - AndHealth Autoimmune Research Registry NCT05883371 | AndHealth | — |
| Unknown | The Impact of Different Relaxation Techniques on Psoriasis Patients With an Elevated Psychological Stress Leve NCT05894759 | Grigore T. Popa University of Medicine and Pharmacy | N/A |
| Completed | Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study). NCT06125808 | Arctic Bioscience | Phase 2 |
| Completed | Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque P NCT05863273 | First Hospital of China Medical University | — |
| Unknown | A Study of QY101 Ointment in Subjects With Plaque Psoriasis NCT06170840 | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Phase 2 |
| Recruiting | Determinants of Chronic Inflammatory Skin Disease Trajectories NCT05928169 | University Hospital Schleswig-Holstein | — |
| Completed | A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaqu NCT05728489 | Boehringer Ingelheim | Phase 1 |
| Completed | A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers NCT05718921 | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Phase 1 |
| Completed | A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis NCT05730725 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis NCT06066125 | Akeso | Phase 3 |
| Unknown | Chinese Medicine for Patients With Psoriasis NCT05295979 | Chinese University of Hong Kong | Phase 2 |
| Completed | A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and NCT05789576 | Organon and Co | Phase 4 |
| Recruiting | Value Based Healthcare in Psoriasis NCT05480917 | University Hospital, Ghent | N/A |
| Completed | Vtama in Psoriasis Patients Being Treated With Biologics. NCT06103695 | Psoriasis Treatment Center of Central New Jersey | Phase 4 |
| Completed | Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers NCT05734482 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 1 |
| Completed | A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis NCT05645627 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Completed | INulin-type Fructans-induced Gut Microbiota Modulation Impact on GUT-SKIN Axis Parameters in Psoriasis NCT05971992 | Polish Academy of Sciences | N/A |
| Active Not Recruiting | A Herbal Compound for Psoriasis NCT06301997 | Fasa University of Medical Sciences | Phase 2 |
| Completed | Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patien NCT06408454 | Kahramanmaras Sutcu Imam University | — |
| Recruiting | Multi-modal Quantitative Imaging of the Skin NCT06989216 | HJN Sverige AB/Neko Health | — |
| Completed | A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in NCT05701995 | Bristol-Myers Squibb | Phase 4 |
| Completed | The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis NCT05770271 | Dove Medical Press Ltd | N/A |
| Completed | Effect of Long-term Psoriasis on Patients' Life - CORONATE NCT05555953 | AbbVie | — |
| Completed | Periodontal Status in Patients With Chronic Skin Diseases NCT06073613 | University of Medicine and Pharmacy at Ho Chi Minh City | — |
| Active Not Recruiting | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps NCT05866614 | Celltrion | — |
| Completed | Roflumilast Versus Methotrexate in Psoriasis NCT05684744 | Cairo University | Phase 2 / Phase 3 |
| Completed | A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate NCT05536726 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 |
| Recruiting | Immunoclassification of Psoriasis: a Strategy for Precision Medicine NCT05503875 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Completed | A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis NCT05680740 | Organon and Co | Phase 4 |
| Completed | Topical SGX302 for Mild-to-Moderate Psoriasis NCT05442190 | Soligenix | Phase 2 |
| Terminated | Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Pso NCT04305327 | LEO Pharma | Phase 3 |
| Completed | Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis NCT05706870 | GEN İlaç ve Sağlık Ürünleri A.Ş. | Phase 2 |
| Completed | Combination of Sotyktu and Enstilar for Plaque Psoriasis NCT06329258 | Psoriasis Treatment Center of Central New Jersey | Phase 4 |
| Completed | A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan NCT05633264 | Bristol-Myers Squibb | — |
| Terminated | VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis NCT05655299 | Ventyx Biosciences, Inc | Phase 2 |
| Completed | Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Data NCT06172426 | Novartis Pharmaceuticals | — |
| Recruiting | Meditation in Inflammatory Dermatosis NCT05500794 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics NCT05270733 | University Hospitals Cleveland Medical Center | Phase 4 |
| Unknown | The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis NCT05184699 | University of Athens | N/A |
| Completed | A Study to Assess Treatment Patterns, Clinical Outcomes and Healthcare Resource Utilization Among Adult Partic NCT05547490 | Bristol-Myers Squibb | — |
| Unknown | Excimer Laser With Topical Agents in Psoriasis Vulgaris NCT05555797 | Assiut University | Phase 4 |
| Completed | Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic D NCT05571696 | Elaine Husni | N/A |
| Completed | A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the NCT05758402 | Novartis Pharmaceuticals | N/A |
| Completed | The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis NCT05589298 | Skane University Hospital | — |
| Recruiting | Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treate NCT06399432 | University Hospitals Cleveland Medical Center | N/A |
| Unknown | Response of Metabolic Syndrome and Sexual Dysfunction to Lifestyle Changes in Men With Psoriasis NCT05632042 | Cairo University | N/A |
| Terminated | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis NCT06005792 | Xencor, Inc. | Phase 1 |
| Completed | Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis NCT05478499 | Bristol-Myers Squibb | Phase 4 |
| Recruiting | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaq NCT05744466 | Bristol-Myers Squibb | — |
| Completed | Ethoximod Pharmacokinetics In Healthy Subjects NCT06361212 | Longevity Inc. | Phase 1 |
| Recruiting | Cytokine Expression in Psoriasis Patients with and Without Joint Involvement NCT05307809 | Poitiers University Hospital | N/A |
| Completed | Improving Disease Severity NCT05391178 | Wake Forest University Health Sciences | N/A |
| Completed | Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis NCT07140666 | Chongli Yu | — |
| Completed | Prediction Model for Osteopenia in Patients With Psoriasis NCT07112755 | Chongli Yu | — |
| Unknown | A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis NCT05451199 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Completed | Role of Intermittent Fasting in Psoriasis and Psoriatic Arthritis NCT05590247 | Ohio State University | N/A |
| Completed | Tunisian National Registry on Psoriasis NCT05258838 | Dacima Consulting | — |
| Completed | A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Part NCT05453942 | Sanofi | Phase 1 |
| Recruiting | Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis NCT05399433 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Monitoring of Inflammatory Conditions NCT05458531 | University of Nottingham | — |
| Completed | Asking People With Psoriasis About Lifestyle and Eating NCT05448352 | King's College London | — |
| Completed | Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases NCT05406908 | Mahidol University | Phase 4 |
| Completed | Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects NCT04711343 | Bio-Thera Solutions | Phase 1 |
| Completed | Biofeedback for Psoriasis NCT05506644 | Bastyr University | N/A |
| Completed | The Disease Severity In Patients With Psoriasis NCT05943405 | Universitas Sebelas Maret | — |
| Completed | A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis NCT05252533 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. NCT05311501 | University of Siena | N/A |
| Unknown | JAK-STAT Signaling Pathway in Pyoderma Gangrenosum NCT04792957 | Dokuz Eylul University | — |
| Recruiting | Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidat NCT04751396 | M.D. Anderson Cancer Center | — |
| Completed | Effects of Tildrakizumab on Epigenetic Age NCT05110313 | Carlos Wambier | Phase 4 |
| Completed | Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% NCT05461456 | OrchestratePharma GmbH | Phase 1 |
| Unknown | Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis NCT05326659 | Peking University People's Hospital | N/A |
| Recruiting | Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques NCT05642182 | SFA Therapeutics | Phase 1 |
| Completed | Phase I Study of GN-037 Cream for Psoriasis NCT05428202 | TC Erciyes University | Phase 1 |
| Completed | Excimer Light in Psoriasis NCT05283876 | Cairo University | N/A |
| Completed | Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis NCT06043752 | Ghurki Trust and Teaching Hospital | Phase 4 |
| Completed | Safety and Tolerability Study of MSC Exosome Ointment NCT05523011 | Paracrine Therapeutics Dermatology Pte. Ltd. | Phase 1 |
| Completed | Efficacy and Safety of Apremilast in Psoriasis NCT06032858 | Ghurki Trust and Teaching Hospital | Phase 4 |
| Completed | High Dose Risankizumab for Psoriasis NCT05283135 | Oregon Medical Research Center | Phase 2 |
| Unknown | Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis. NCT05252741 | Sohag University | N/A |
| Recruiting | Multi-Center PAMPA Study NCT05004727 | NYU Langone Health | Phase 4 |
| Active Not Recruiting | Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLA NCT05185258 | Aarhus University Hospital | Phase 4 |
| Completed | Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phas NCT04535999 | University of Pennsylvania | Phase 4 |
| Unknown | UVB-induced Treg Cells Exert Antigen-specific Suppression Through LAG-3 NCT05636839 | National Taiwan University Hospital | N/A |
| Completed | A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis NCT04839328 | Tianjin Hemay Pharmaceutical Co., Ltd | Phase 3 |
| Unknown | Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis NCT05427175 | Aswan University Hospital | Phase 4 |
| Completed | Subclinical Impairment of Cardiovascular System in Patients With Psoriasis NCT05957120 | University Medical Centre Ljubljana | — |
| Recruiting | Psorcast Mobile Study NCT05621369 | Sage Bionetworks | — |
| Completed | Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis NCT06555497 | Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium | EARLY_Phase 1 |
| Completed | Study to Assess the Efficacy and Safety of Orismilast in Psoriasis NCT05190419 | UNION therapeutics | Phase 2 |
| Completed | A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream NCT05514353 | Pyramid Biosciences | Phase 1 |
| Completed | Pleiotropic Role of TRPV1 in Psoriasis Inflammation NCT04848194 | University Hospital, Brest | N/A |
| Recruiting | Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL NCT05111210 | Institut Pasteur | — |
| Enrolling By Invitation | Quest to Analyze One Thousand Humans Meditating NCT06583395 | Tobias Moeller-Bertram | — |
| Terminated | Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque P NCT05125679 | Janssen-Cilag Ltd. | Phase 4 |
| Terminated | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Mo NCT05044234 | AbbVie | Phase 2 |
| Unknown | Validation of a Dermatology-Specific Treatment Satisfaction Instrument NCT05056168 | University of Southern California | — |
| Completed | A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects NCT06033742 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines NCT05144165 | Centre of Evidence of the French Society of Dermatology | — |
| Completed | Hypertension, Antihypertensive Medication Use, and Risk of Psoriasis NCT06075394 | Xijing Hospital | — |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Active Not Recruiting | Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Li NCT05132231 | Bausch Health Americas, Inc. | — |
| Recruiting | ProspectIve Cohort psoriASiS fOllow-up (PICASSO) NCT05122039 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic NCT05098600 | Faculty Hospital Kralovske Vinohrady | — |
| Unknown | Topical Methotrexate Microemulsion in the Treatment of Plaque Psoriasis NCT04971239 | Assiut University | Phase 4 |
| Unknown | Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients NCT05076812 | Sohag University | — |
| Completed | Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Dis NCT05065762 | Bristol-Myers Squibb | — |
| Completed | Cardiovascular Risk Predictors in Patients With Psoriasis NCT05200598 | I.M. Sechenov First Moscow State Medical University | — |
| Completed | A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinu NCT04894890 | Novartis Pharmaceuticals | — |
| Completed | A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis NCT05003531 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Unknown | Lifestyle Modification in Psoriatic Patients With Fatty Liver NCT05125757 | Cairo University | N/A |
| Completed | Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis NCT04841187 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis NCT07169682 | National and Kapodistrian University of Athens | — |
| Recruiting | Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis NCT04950218 | Herlev and Gentofte Hospital | — |
| Unknown | Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis NCT03745417 | Guangdong Provincial Hospital of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Completed | A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis NCT04914429 | Janssen Research & Development, LLC | Phase 4 |
| Recruiting | Metabolic Profiling of Immune Responses in Immune-mediated Diseases NCT04864886 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging NCT05135312 | OptiSkin Medical | Phase 4 |
| Unknown | Subjects Through the Application of the Mindera Kit Part 2 NCT04904315 | Mindera Health | — |
| Unknown | MBCT for Psoriasis Patients With Anxiety and Depression NCT05010044 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Completed | A Study of LY3361237 in Participants With Psoriasis NCT04975295 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Mo NCT04862286 | AbbVie | Phase 3 |
| Completed | A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaqu NCT04967508 | Samsung Bioepis Co., Ltd. | Phase 3 |
| Completed | A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors NCT04776629 | Abcentra | Phase 2 |
| Completed | Brain Changes in Psoriasis After Secukinumab Treatment NCT04717466 | University of Miami | Phase 4 |
| Completed | A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan NCT04826536 | Bristol-Myers Squibb | — |
| Withdrawn | Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Ps NCT04799990 | AbbVie | — |
| Completed | Anti-Inflammatory Effects of Time-Restricted Feeding NCT04728165 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease A NCT04908475 | AbbVie | Phase 4 |
| Terminated | Effect of Chronic Inflammation on Myocardial Perfusion and Function NCT04870827 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Unknown | Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients . NCT05401006 | South Valley University | Phase 4 |
| Completed | Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis NCT04930042 | Alvotech Swiss AG | Phase 3 |
| Unknown | Phase IV Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Psoriasis in Adults NCT05064748 | Peking University People's Hospital | Phase 4 |
| Completed | Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Partici NCT04818385 | AbbVie | — |
| Completed | Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) NCT04744363 | Alvotech Swiss AG | Phase 1 |
| Completed | Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects NCT04837235 | Tianjin Hemay Pharmaceutical Co., Ltd | Phase 1 |
| Completed | A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis NCT05096364 | Akeso | Phase 2 |
| Active Not Recruiting | Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated Wit NCT04780516 | AbbVie | — |
| Active Not Recruiting | Risankizumab Long-term Remission Study NCT04630652 | Jaehwan Kim | Phase 4 |
| Completed | Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults NCT04843631 | BioFactura Australia Pty Ltd. | Phase 1 |
| Completed | Relationships Among Inflammation, Physical and Mental Health in Subjects With Chronic Inflammatory Physical Di NCT05125458 | University of Campania Luigi Vanvitelli | — |
| Withdrawn | SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE NCT04417114 | Brigham and Women's Hospital | Phase 4 |
| Unknown | Shortening Treatments Of Chronic Inflammatory Conditions NCT04848649 | Centre Hospitalier Universitaire de Besancon | N/A |
| Unknown | A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate NCT05604898 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Completed | A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis NCT03988439 | Bausch Health Americas, Inc. | Phase 4 |
| Completed | A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe NCT04761627 | Amgen | Phase 3 |
| Completed | Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis NCT05513014 | Novartis Pharmaceuticals | — |
| Completed | The Diagnostic Ultrasound Enthesitis Tool (DUET) Study NCT04587362 | Women's College Hospital | — |
| Unknown | Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis NCT04785027 | Guangdong Provincial Hospital of Traditional Chinese Medicine | Phase 1 / Phase 2 |
| Withdrawn | Iontophoresis in Psoriasis NCT03979664 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) NCT04746911 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Par NCT04713592 | AbbVie | Phase 3 |
| Completed | Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasi NCT04927195 | Evelo Biosciences, Inc. | Phase 1 |
| Unknown | Non-invasive Photoacoustic Imaging of Skin Inflammatory Disorders With Machine Learning-assisted Scoring NCT04809571 | Institute of Bioengineering and Bioimaging (IBB) | N/A |
| Completed | Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) NCT05320159 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Metabolic Biomarkers in Hashimoto's Thyroiditis and Psoriasis NCT04693936 | University of Crete | N/A |
| Withdrawn | Neuroinflammation, Affective and Cognitive Symptoms in Major Depression and Psoriasis NCT04423471 | Germans Trias i Pujol Hospital | — |
| Unknown | Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity NCT04722640 | Istituto Clinico Humanitas | Phase 4 |
| Unknown | Prevalence of Periodontitis in Patients With Plaque Psoriasis. A Cross-sectional Study NCT04722094 | University of Siena | — |
| Completed | Rimegepant in Moderate Plaque-type Psoriasis NCT04629950 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis NCT04673786 | Celltrion | Phase 3 |
| Unknown | Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients NCT04680624 | Association pour la Recherche Clinique et Immunologique | N/A |
| Completed | Efficacy of Roflumilast in the Treatment of Psoriasis NCT04549870 | Bispebjerg Hospital | Phase 2 |
| Terminated | Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequa NCT04533737 | LEO Pharma | Phase 4 |
| Unknown | Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis NCT04811911 | Aswan University Hospital | Phase 4 |
| Unknown | the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis NCT04912401 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfac NCT04765332 | Clinact | — |
| Completed | Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions NCT04560647 | Wright State University | — |
| Completed | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215) NCT04655313 | Arcutis Biotherapeutics, Inc. | Phase 2 |
| Completed | Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients NCT04633616 | University of Southern California | N/A |
| Completed | Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug- NCT04410237 | University Hospitals Cleveland Medical Center | EARLY_Phase 1 |
| Withdrawn | An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured NCT04488185 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Dietary Perceptions and Practices in Chinese Psoriasis Patients NCT05118425 | Xijing Hospital | — |